ORIGINAL INVESTIGATION. Thrombolysis vs Heparin in the Treatment of Pulmonary Embolism
|
|
- George Curtis
- 6 years ago
- Views:
Transcription
1 Thrombolysis vs Heparin in the Treatment of Pulmonary Embolism A Clinical Outcome Based Meta-analysis ORIGINAL INVESTIGATION Giancarlo Agnelli, MD; Cecilia Becattini, MD; Timo Kirschstein, MD Background: In patients with acute pulmonary embolism, thrombolysis results in a more rapid resolution of pulmonary emboli than heparin treatment. Whether this advantage results in an improved clinical outcome is unclear. We sought to perform a clinical outcome based metaanalysis of studies comparing thrombolytic and heparin treatment in patients with pulmonary embolism. Methods: Data concerning adverse outcome events (death, recurrent pulmonary embolism, and major bleeding events) were extracted from the identified randomized studies. Results: A total of 56 (23.2%) of 241 patients treated with thrombolytic agents in 9 randomized trials experienced an adverse outcome event compared with 57 (25.9%) of 220 patients treated with heparin (relative risk [RR], 0.9; 95% confidence interval [CI], ). In the thrombolysis group, 11 patients (4.6%) died compared with 17 (7.7%) in the heparin group (RR, 0.59; 95% CI, ). Thirty-one patients (12.9%) undergoing thrombolysis had a major bleeding episode compared with 19 patients (8.6%) treated with heparin (RR, 1.49; 95% CI, ). Five fatal bleeding episodes (2.1%) occurred in the thrombolysis group and none in the heparin group. Six studies provided data on recurrent pulmonary embolism. A recurrence occurred in 14 (6.6%) of 214 patients treated with thrombolytic agents and in 22 (10.9%) of 201 patients treated with heparin (RR, 0.60; 95% CI, ). Recurrence and/or death occurred in 25 (10.4%) of 241 and in 38 (17.3%) of 220 patients treated with thrombolytic agents and heparin, respectively (RR, 0.55; 95% CI, ; P=.03). Conclusions: In patients with pulmonary embolism, thrombolysis had a lower composite end point of death/ recurrence than heparin treatment. Excessive bleeding is the trade-off for improved efficacy. A comparative clinical outcome trial of thrombolysis and heparin treatment is warranted in patients with pulmonary embolism and selected for high risk of death and/or recurrence and low risk of bleeding. Arch Intern Med. 2002;162: From the Department of Internal Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy. PULMONARY EMBOLISM is a common and life-threatening disease. The incidence of a first episode of pulmonary embolism in acute care hospitals in the United States has been found to be 0.23 per In the 1960s, the introduction of heparin for treatment of pulmonary embolism cut down in-hospital mortality, 2 but since then no further reduction has been achieved. 3 Thrombolytic agents provide a more rapid lysis of pulmonary emboli and reduction of pulmonary hypertension than heparin. 4 Whether these advantages result in an improved clinical outcome and outweigh the increased risk of bleeding complications is unknown. No conclusive clinical outcome studies aimed at comparing thrombolysis and heparin treatment in patients with pulmonary embolism are available. We performed a meta-analysis of studies comparing thrombolysis and heparin treatment in patients with pulmonary embolism with respect to the occurrence of death, recurrence of pulmonary embolism, and bleeding events. METHODS STUDY SELECTION Randomized clinical trials comparing thrombolysis and heparin for treatment of pulmonary embolism were identified by computeraided search (MEDLINE), scan of meeting abstracts, and scrutiny of the reference lists of For editorial comment see page 2521 original research and review articles. Trials were included in this meta-analysis if data concerning death and major bleeding events were avail- 2537
2 Table 1. Randomized Clinical Trials Comparing Thrombolytic and Heparin Treatment in Patients With Pulmonary Embolism* PE Assessment Primary Outcome Source Double-blind N Treatment UPET 4 No 82 UK: 2000 U/lb bolus, AGF, LS AGF hemodynamic 2000 U/lb for 12 h improvement 78 Heparin Tibbutt et al 8 No 13 Intrapulmonary SK: U bolus, U/h for 72 h 17 Intrapulmonary heparin Ly et al 9 No 14 SK: U bolus, U/h for 72 h 11 Heparin Marini et al 10 No 10 UK: U/12 h for 3d 10 UK: U/12 h 10 Heparin PAIMS 2 11 No 20 rt-pa: 100 mg/2 h AGF AGF reperfusion and hemodynamic improvement Observation Period Criteria for Patient Selection 14 d Confirmed PE AGF AGF reperfusion 72 h Life-threatening PE AGF AGF reperfusion 72 h PE involving 1 lobar artery AGF, LS LS reperfusion 12 mo Perfusion defect 9 segments at LS 20 d Miller index Heparin Goldhaber et al 12 No 46 rt-pa: 100 mg/2 h AGF, LS RVD regression 14 d PE associated with RVD 55 Heparin Jerjes-Sanchez et al 13 No 4 SK: U/1 h AGF LS reperfusion Hospital stay Perfusion defect 9 segments at LS or perfusion defect 9 segments at LS + RVD 4 Heparin PIOPED 14 Yes 9 rt-pa: mg/40-90 min 4 Heparin Levine et al 15 Yes 33 rt-pa: 0.6 mg/kg every 2 min 25 Heparin AGF, LS PAP reduction at AGF Hospital stay PE involving 2 segmental arteries AGF, LS LS reperfusion 10 d Confirmed PE *PE indicates pulmonary embolism; UPET, Urokinase Pulmonary Embolism Trial; PAIMS 2, Plasminogen Activator Italian Multicenter Study 2; PIOPED, Prospective Investigation of Pulmonary Embolism Diagnosis; UK, urokinase; SK, streptokinase; rt-pa, recombinant tissue-type plasminogen activator; AGF, angiography; LS, lung scan; RVD, echocardiographical right ventricular dysfunction; and PAP, pulmonary artery pressure. able. Data extraction from the individual trials was independently performed by the authors. Discrepancy between the results obtained by the authors concerning selection and extraction of data was resolved by consensus. OUTCOMES The primary outcome of this meta-analysis was the incidence of adverse clinical outcome events (death, recurrence of pulmonary embolism, and major bleeding events). Recurrence of pulmonary embolism was considered among the adverse clinical outcome events, when reported, because it has been recently shown to be a predictor of in-hospital mortality. 5 An analysis of the overall bleeding events (major and minor) was performed. For the purpose of this analysis, bleeding was considered major when it was fatal, intracranial, associated with a decrease in hemoglobin level of at least 2 g/dl, or it required the transfusion of 2 or more units of red blood cells. Data on patients with intracranial and fatal bleeding were extrapolated from the more general population data of patients with major bleeding. Bleeding events were also considered separately as associated or not with invasive procedures. STATISTICAL ANALYSIS No assumption regarding the comparability of patients between the different studies was used because all the statistical calculations are based on the comparison within each single trial. Nevertheless, the homogeneity of the studies was tested with an approximate 2 statistic. The analysis was performed cumulatively for the overall adverse outcome events, separately for each adverse outcome event (death, major bleeding event, and recurrence of pulmonary embolism), and for death and recurrence together. To avoid the overestimation of adverse events, patients with multiple events were counted only once. The relative risk (RR), the approximate odds ratio with its corresponding 95% confidence interval (CI), and a 2-tailed P value were calculated for each trial and for the overall results. The number needed to treat and the number needed to harm were also indicated when appropriate. The results of each trial were analyzed on an intention-to-treat basis. RESULTS Eleven clinical trials comparing thrombolysis and heparin use for the treatment of pulmonary embolism were identified. Two trials were excluded from this analysis because they were nonrandomized. 6,7 Therefore, 9 randomized trials, 4, of which were double-blind, 14,15 were included in this analysis (Table 1). Patients included 2538
3 Table 2. Adverse Outcome Events* 1 AOE, Death, Major Bleeding, Recurrence, Source T-lysis Heparin RR (95% CI) T-lysis Heparin RR (95% CI) T-lysis Heparin OR (95% CI) T-lysis Heparin RR (95% CI) UPET 7 40/82 36/ ( ) 6/82 7/ ( ) 21/82 11/ ( ) 13/82 18/ ( ) Tibbutt et al 8 1/13 2/ ( ) 0/13 1/17 0 ( ) 1/13 1/ ( ) 0/13 1/17 0 Ly et al 9 3/14 3/ ( ) 1/14 2/ ( ) 2/14 1/ ( ) Marini et al 10 0/20 0/10 0/20 0/10 NE 0/20 0/10 0/20 0/10... PAIMS /20 3/ ( ) 2/20 1/ ( ) 1/20 2/ ( ) 1/20 0/16... Goldhaber 3/46 6/ ( ) 0/46 2/55 0 ( ) 3/46 1/ ( ) 0/46 3/55 0 et al 12 Jerjes-Sanchez 0/4 4/4 0 0/4 4/4 0 (0-0.77) 0/4 0/4 NE et al 13 PIOPED 14 1/9 0/4 NE 1/9 0/4 NE 0/9 0/4 NE Levine et al 15 4/33 3/ ( ) 1/33 0/25 NE 3/33 3/ ( ) 1/33 0/25... All Studies 56/241 57/ ( ) 11/241 17/ ( ) 31/241 19/ ( ) 14/214 22/ ( ) *AOE indicates adverse outcome event; T-lysis, thrombolytic treatment; RR, relative risk; CI, confidence interval; OR, odds ratio; UPET, Urokinase Pulmonary Embolism Trial; PAIMS 2, Plasminogen Activator Italian Multicenter Study 2; PIOPED, Prospective Investigation of Pulmonary Embolism Diagnosis; and NE, not evaluable. UPET 4 Tibbutt et al 8 Ly et al 9 Marini et al 10 Goldhaber et al 12 PAIMS 2 11 Jerjes-Sanchez et al 13 PIOPED 14 Levine et al 15 All Studies Thrombolysis Better Heparin Better Odds Ratio Plot of the approximate odds ratios and 95% confidence intervals for death, recurrence of pulmonary embolism, or major bleeding event in the patients of the 9 studies analyzed and for the pooled data. The dotted line indicates the odds ratios across all studies. in double-blind studies accounted for 15.4% of the overall study population. Overall, 461 patients were included in the analysis: 241 (52.3%) received thrombolytic therapy with streptokinase (31 patients), urokinase (102 patients), or recombinant tissue-type plasminogen activator (108 patients) in different doses and regimens, while 220 patients received heparin. The study end point was pulmonary reperfusion as assessed by angiography and/or by lung scan in most of the studies included in the analysis. With a single exception, 9 the observation period was limited to the hospital stay, and no data were provided on the long-term clinical outcome (Table 1). Adverse clinical events, death, recurrence of pulmonary embolism, and major bleeding events were first analyzed cumulatively. Across all studies, adverse clinical events occurred in 56 patients (23.2%) treated with thrombolytic agents and in 57 patients (25.9%) treated with heparin, resulting in an RR of 0.9 (95% CI, ; P=.51) (Table 2 and Figure). In the thrombolysis group, 11 patients (4.6%) died compared with 17 patients (7.7%) treated with heparin, corresponding to an RR of 0.59 (95% CI, ; P=.51; number needed to treat, 31.6) (Table 2). Thirty-one patients undergoing thrombolysis (12.9%) had major bleeding events compared with 19 (8.6%) treated with heparin, corresponding to an RR of 1.49 (95% CI, ; number needed to harm, 23). Overall, 5 patients, all of them in the thrombolysis group (2.1%), had a fatal bleeding event. Fatal bleeding events were as follows: 3 gastrointestinal, 1 intracranial, and 1 cardiac tamponade. One additional patient undergoing thrombolysis died and had intracranial bleeding, but death was attributed to the recurrence of pulmonary embolism. In 5 of the 9 studies, invasive procedures were performed, essentially catheter insertion for pulmonary angiography. 4,8,9,11,14 The incidence of major bleeding was 15.2% (40/264) in studies requiring invasive procedures and 5.1% (10/197) in the remaining studies (RR, 2.98; 95% CI, ; P<.001). The incidence of major bleeding in patients receiving thrombolytic treatment in studies with and without invasive procedures was 18.1% (25/138) and 5.8% (6/103), respectively (RR, 3.1; 95% CI, ; P<.005). The incidence of major bleeding in patients receiving heparin in studies with and without invasive procedures was 11.9% (15/126) and 4.3% (4/94), respectively (RR, 2.80; 95% CI, ; P<.05). Four trials reported adequate data on overall bleeding events (major and minor), 4,10,11,15 the rate ranging from 5% to 70% in the thrombolysis group and from 0% to 50% in the heparin group (Table 3). The rate of overall bleeding events was 42.6% and 26.0% in patients receiving thrombolysis and heparin, respectively, corresponding to an RR of 1.99 (95% CI, ; P<.001). A statistically significant increase of overall bleeding in patients undergoing thrombolysis was observed in 1 double-blind trial. 15 Six studies, 4,8,10,11,12,15 including 415 patients, reported the incidence of recurrence of pulmonary embolism (Table 2). This event occurred in 14 (6.6%) of 214 patients treated with thrombolysis and in 22 of the 201 patients treated with heparin, corresponding to an RR of 0.60 (95% CI, ). When death and recurrence were considered together, an RR of 0.57 (95% CI,
4 Table 3. Total Bleeding Events* Total Bleeding, (%) Source Thrombolysis Heparin OR (95% CI) P Value UPET 7 37/82 (45) 21/78 (27) 2.23 ( ).02 Marini et al 10 1/20 (5) 0/10... ( ).47 PAIMS /20 (70) 6/16 (38) 3.89 ( ).051 Levine et al 15 15/33 (45) 1/25 (4) ( ).001 All Studies 67/155 (43.2) 28/129 (21.7) 2.75 ( ).001 *OR indicates odds ratio; CI, confidence interval; UPET, Urokinase Pulmonary Embolism Trial; and PAIMS 2, Plasminogen Activator Italian Multicenter Study ; P=.03) in favor of thrombolysis was observed. For death and recurrence taken together, the number needed to treat was Streptokinase, urokinase, and recombinant tissuetype plasminogen activator were used in 3, 2, and 4 studies, respectively (Table 1). The overall mortality was 8.3% (21/253) in patients included in the streptokinase and urokinase studies, while it was 3.4% (7/208) in patients included in the recombinant tissue-type plasminogen activator studies (RR, 0.41; 95% CI, ). The overall incidence of major bleeding events in patients included in the streptokinase and urokinase studies was 14.6% (37/253), while it was 6.3% (13/208 patients) in patients included in the recombinant tissue-type plasminogen activator studies (RR, 0.43; 95% CI, ). Among patients receiving thrombolysis, the incidence of major bleeding was 18.1% (24/133) in patients receiving streptokinase or urokinase and 6.5% (7/108) in patients receiving recombinant tissue-type plasminogen activator (RR, 0.36; 95% CI, ). The incidence of major bleeding was similar in patients receiving heparin in the streptokinase or urokinase studies (10.8%) and in the recombinant tissue-type plasminogen activator studies (6.0%) (RR, 0.55; 95% CI, ). In the non double-blind studies, 25.6% of the patients receiving thrombolytic therapy experienced an adverse event compared with 28.3% in the heparin group (RR, 0.91; 95% CI, ). In the 2 double-blind studies, 11.9% of the patients receiving thrombolytic therapy experienced an adverse event compared with 10.3% in the heparin group, 14,15 corresponding to an RR of 1.15 (95% CI, ). COMMENT Most of the studies included in the present metaanalysis were designed to compare the effect of thrombolysis and heparin treatment on the rate and the speed of lung reperfusion in patients with pulmonary embolism. This meta-analysis focused on the occurrence of adverse clinical outcome events such as death, recurrence of pulmonary embolism, and major bleeding. A risk reduction of 41% and 40% in favor of thrombolysis was observed for death and recurrence, respectively. When death and recurrence were analyzed together, a statistically significant risk reduction in favor of thrombolysis was observed. The overall death rate across the studies was 6.1%. This death rate is lower than that observed in 2 recent registries in patients with pulmonary embolism. 5,16 Indeed, the mortality rate was 9.6% during the in-hospital stay and 11.4% at 2-week follow-up in the Management and Prognosis of Pulmonary Embolism Trial (MAPPET) registry 16 and International Cooperative Pulmonary Embolism Registry (ICOPER), 5 respectively. The low death rate observed in the present meta-analysis suggests that patients at relatively low risk for adverse outcome were included in the analyzed studies. The inclusion of a lowrisk population could not have favored the thrombolysis that conceivably should be particularly advantageous over heparin treatment in cases of severe pulmonary embolism. The rate of major bleeding was 12.9% in patients receiving thrombolysis and 8.6% in patients receiving heparin treatment. These rates were influenced by the frequent use of invasive procedures, essentially catheter insertion for pulmonary angiography. This was particularly the case for patients receiving thrombolytic treatment. The rate of intracranial bleeding in patients receiving thrombolysis for pulmonary embolism was 0.8%, similar to that reported in patients with myocardial infarction treated with thrombolysis. 17 The results of this analysis make critical the selection of patients with pulmonary embolism who could benefit from thrombolytic therapy. Indeed, this treatment should be reserved for patients at high risk for death and recurrence and at low risk for bleeding. The identification of a high-risk population could be facilitated by the finding of right ventricular dysfunction at echocardiography, which has been shown to be a predictor of inhospital mortality 18,19 and recurrence. 20 Careful patient selection and the use of noninvasive diagnostic methods for pulmonary embolism could contribute to the reduction of adverse bleeding events. The results of the present meta-analysis could have been influenced by the use of suboptimal thrombolytic agents and/or regimens. It should be noted that the thrombolysis treatments used in the analyzed trials differ largely in choice of thrombolytic agent and regimen. Indeed, some of the regimens used in the first studies are not conceivable nowadays. It is of interest that the incidence of death and major bleeding events was significantly higher in patients receiving streptokinase or urokinase than in patients receiving recombinant tissuetype plasminogen activator. This reading of the results leaves open the possibility that more effective and safer thrombolytic agents, administered in a more pharmacologically sound regimen, including shorter infusion 2540
5 time, could produce a higher clinical benefit in terms of safety and efficacy. The studies included in our meta-analysis provide information limited to the short-term clinical outcome of patients with pulmonary embolism. Thus, it does not test the hypothesis that thrombolytic therapy could produce long-term clinical advantages such as a lower incidence of late recurrence of pulmonary embolism or chronic thromboembolic pulmonary hypertension. In conclusion, the present meta-analysis of comparative studies in pulmonary embolism showed that death and recurrences are less frequent with thrombolysis than with heparin treatment. The excessive bleeding mainly associated with invasive procedures is the tradeoff for this improved efficacy. A comparative clinical outcome trial of thrombolysis and heparin treatment in patients with pulmonary embolism and with a high risk of death and/or recurrence and a low risk of bleeding is warranted and should not be further delayed. Accepted for publication May 2, Corresponding author: Giancarlo Agnelli, MD, Sezione di Medicina Interna e Cardiovascolare, Dipartimento di Medicina Interna, Università degli Studi di Perugia, Via Enrico dal Pozzo, I Perugia, Italy ( REFERENCES 1. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep-vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991;151: Barrit DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet. 1960;1: Goldhaber SZ. Contemporary pulmonary embolism thrombolysis. Chest. 1995; 107:45S-51S. 4. The Urokinase Pulmonary Embolism Trial: a national cooperative study. Circulation. 1973;47(suppl 2): Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry. Lancet. 1999;353: Miller GAH, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. BMJ. 1971;2: Konstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol. 1998;82: Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. BMJ. 1974;1: Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand. 1978;203: Marini C, Di Ricco G, Rossi R, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration. 1988;54: Dalla-Volta S, Palla A, Santolicandro A, et al. Plasminogen Activator Italian Multicenter Study 2 (PAIMS 2): alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. J Am Coll Cardiol. 1992;20: Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341: Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2: The PIOPED investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism. Chest. 1990;97: Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. 1990;98: Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism. Circulation. 1997;96: Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343: Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with pulmonary embolism, normal blood pressure and echocardiographic right ventricular dysfunction. Circulation. 2000;101: Ribeiro A. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J. 1997;134: Wolfe MW. Prognostic significance of right ventricular hypokinesis and perfusion lung scan defects in pulmonary embolism. Am Heart J. 1994;127:
Pulmonary embolism remains a major cause of morbidity
Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism A Meta-Analysis of the Randomized Controlled Trials Susan Wan; Daniel J. Quinlan, MBBS; Giancarlo Agnelli, MD; John W.
More informationPulmonary embolism (PE) is a life-threatening. Efficacy of thrombolytic agents in the treatment of pulmonary embolism. T. Capstick* and M.T.
Eur Respir J 2005; 26: 864 874 DOI: 10.1183/09031936.05.00002505 CopyrightßERS Journals Ltd 2005 Efficacy of thrombolytic agents in the treatment of pulmonary embolism T. Capstick* and M.T. Henry # ABSTRACT:
More informationManagement of Massive and Sub-Massive Pulmonary Embolism
Management of Massive and Sub-Massive Pulmonary Embolism M. Montero-Baker, MD L Leon Jr., MD, RVT, FACS Tucson Medical Center Vascular and Endovascular Surgery Section CASE PRESENTATION 54 YEAR- OLD CAUCASIAN
More informationLocal and systemic thrombolytic therapy for acute venous thromboembolism
Clin Chest Med 24 (2003) 73 91 Local and systemic thrombolytic therapy for acute venous thromboembolism Selim M. Arcasoy, MD, FCCP, FACP a,b, *, Anil Vachani, MD c a Pulmonary, Allergy, and Critical Care
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Prognostic Role of Echocardiography Among Patients With Acute Pulmonary Embolism and a Systolic Arterial Pressure of 90 mm Hg or Higher Nils Kucher, MD; Elisa Rossi, BS; Marisa De
More informationEffectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism Perlroth D J, Sanders G D, Gould M K
Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism Perlroth D J, Sanders G D, Gould M K Record Status This is a critical abstract of an economic evaluation that meets
More informationGuideline for Thrombolysis Therapy in Pulmonary Embolism
Guideline for Thrombolysis Therapy in Pulmonary Embolism Dr Jane Strong Consultant Haematologist Trust ref: B24/2016 1. Introduction / Scope All Patients with pulmonary embolism (PE) require rapid risk
More informationCase. Case. Management of Pulmonary Embolism in the ICU
Management of Pulmonary Embolism in the ICU Todd M Bull, M.D. Associate Professor of Medicine Division of Pulmonary Sciences and Critical Care Medicine Pulmonary Hypertension Center University of Colorado
More informationEpidemiology of Pulmonary Embolism (PE)
Why Treat Submassive PE Abstract: Massive Pulmonary Embolism (PE) requires immediate lifesaving intervention for the patient. For the submassive PE patient, characterized by presence of right ventricular
More informationEpidemiology. Update on Pulmonary Embolism. Keys to PE Management 5/5/2014. Diagnosis. Risk stratification. Treatment
Update on Pulmonary Embolism Steven M. Dean, DO, FACP, RPVI Program Director- Vascular Medicine Associate Professor of Internal Medicine Division of Cardiovascular Medicine The Ohio State University Keys
More informationShould thrombolysis have a greater role in the management of pulmonary embolism?
ORIGINAL PAPERS Clinical Medicine 2009, Vol 9, No 5: 431 5 Should thrombolysis have a greater role in the management of pulmonary embolism? Peter O Jenkins, Javed Sultanzadeh, Manasi Bhagwat and Paul F
More informationEvidence-Based Focused Review
Evidence-Based Focused Review The role of thrombolytic therapy in pulmonary embolism Tzu-Fei Wang, 1 Alessandro Squizzato, 2 Francesco Dentali, 2 and Walter Ageno 2 1 Division of Hematology, The Ohio State
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationP ulmonary embolism (PE) remains a common
766 REVIEW When should we thrombolyse patients with pulmonary embolism? A systematic review of the literature T Harris, S Meek... The early mortality in pulmonary embolism (PE) is largely predicted by
More informationThrombolysis in PE. Outline. Disclosure. Overview on Pulmonary Embolism. Hot Topics in Emergency Medicine 2012 Midyear Clinical Meeting
Disclosure Thrombolysis in PE Daniel P. Hays, PharmD, BCPS, FASHP reports no relevant financial relationships. Daniel P. Hays, PharmD, BCPS, FASHP Outline 55 YOF presents to ED with SOB PMH of DVT + noncompliance
More informationManagement of Acute Pulmonary Embolism. Judith Hurdman Consultant Respiratory Physician
Management of Acute Pulmonary Embolism Judith Hurdman Consultant Respiratory Physician Judith.hurdman@sth.nhs.uk Overview Risk Stratification Who can be managed as an outpatient? To thrombolyse or not
More informationVTE & Medical Patients: Case Scenario
The Saudi Association for Venous Thromboembolism SAVTE The 2 nd SAVTE Symposium 1-3 May, 2012 Casablanca, Morocco VTE & Medical Patients: Case Scenario Majdy Idrees Riyadh, Saudi Arabia Majdy M Idrees,
More informationORIGINAL INVESTIGATION. Thrombolytic Therapy and Mortality in Patients With Acute Pulmonary Embolism
ORIGINAL INVESTIGATION Thrombolytic Therapy and in Patients With Acute Pulmonary Embolism Said A. Ibrahim, MD, MPH; Roslyn A. Stone, PhD; D. Scott Obrosky, MSc; Ming Geng, MSc; Michael J. Fine, MD, MSc;
More informationCritical Review Form Therapy
Critical Review Form Therapy Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion Lancet 1993; 341:501-511 Objective: To determine
More informationInnovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis. Prof. Ralf R.Kolvenbach MD,PhD,FEBVS
Innovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis Prof. Ralf R.Kolvenbach MD,PhD,FEBVS Catheter-based thrombolysis Local administration of lytic agent Higher local
More informationPulmonary Embolism. Pulmonary Embolism. Pulmonary Embolism. PE - Clinical
Pulmonary embolus - a practical approach to investigation and treatment Sam Janes Wellcome Senior Fellow and Respiratory Physician, University College London Background Diagnosis Treatment Common: 50 cases
More informationPULMONARY EMBOLISM. for the last 10 years in randomized studies, showing that
1057 PULMONARY EMBOLISM Comparative Efficacy of a Two-Hour Regimen of Streptokinase Versus Alteplase in Acute Massive Pulmonary Embolism: Immediate Clinical and Hemodynamic Outcome and One-Year Follow-Up
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST IDENTIFYING LOW-RISK PULMONARY EMBOLISM CLINICAL SCORES David Jiménez, MD, PhD Respiratory Department Ramón y Cajal Hospital Madrid, Spain Potential Conflicts of Interest
More informationRyan Walsh, MD Department of Emergency Medicine Madigan Army Medical Center
Ryan Walsh, MD Department of Emergency Medicine Madigan Army Medical Center The opinions expressed herein are solely those of the author and do not represent the official views of the Department of Defense
More informationUse of EKOS Catheter in the management of Venous Mr. Manoj Niverthi, Mr. Sarang Pujari, and Ms. Nupur Dandavate, The GTF Group
Use of EKOS Catheter in the management of Venous Thromboembolism @ Mr. Manoj Niverthi, Mr. Sarang Pujari, and Ms. Nupur Dandavate, The GTF Group Introduction Georgia Thrombosis Forum (GTF, www.gtfonline.net)
More informationPulmonary embolism: Acute management. Cecilia Becattini University of Perugia, Italy
Pulmonary embolism: Acute management Cecilia Becattini University of Perugia, Italy Acute pulmonary embolism: Acute management Diagnosis Risk stratification Treatment Non-high risk PE: diagnosis 3-mo VTE
More informationThrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage A Meta-analysis
Research Original Investigation Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage A Meta-analysis Saurav Chatterjee, MD; Anasua Chakraborty,
More informationOctober 2017 Pulmonary Embolism
October 2017 Pulmonary Embolism Prof. Ahmed BaHammam, FRCP, FCCP Professor of Medicine College of Medicine King Saud University 1 Objectives Epidemiology Pathophysiology Diagnosis Massive PE Treatment
More informationDisclosures. Objectives
BRIGHAM AND WOMEN S HOSPITAL Treatment of Massive and Submassive Pulmonary Embolism Gregory Piazza, MD, MS Assistant Professor of Medicine Harvard Medical School Staff Physician, Cardiovascular Division
More informationSystemic or local thrombolysis in high-risk pulmonary embolism
original article Cardiology Journal 2015, Vol. 22, No. 4, 467 474 DOI: 10.5603/CJ.a2014.0103 Copyright 2015 Via Medica ISSN 1897 5593 Systemic or local thrombolysis in high-risk pulmonary embolism Liviu
More informationDIAGNOSTIC evaluation for acute pulmonary
994 2-D ECHO Jackson et al. ECHOCARDIOGRAPHY FOR PULMONARY EMBOLISM Prospective Evaluation of Two-dimensional Transthoracic Echocardiography in Emergency Department Patients with Suspected Pulmonary Embolism
More informationCardiorespiratory efficacy of thrombolytic therapy in acute massive pulmonary embolism: identification of predictive factors
Eur Respir J 1999; 13: 610±615 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Cardiorespiratory efficacy of thrombolytic therapy in acute
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationChapter 1. Introduction
Chapter 1 Introduction Introduction 9 Even though the first reports on venous thromboembolism date back to the 13 th century and the mechanism of acute pulmonary embolism (PE) was unraveled almost 150
More informationInnovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis. Prof. Ralf R.Kolvenbach MD,PhD,FEBVS
Innovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis Prof. Ralf R.Kolvenbach MD,PhD,FEBVS Conflict of Interest BTG Standard PE therapy ANTICOAGULATION (AC) HEPARIN
More informationRISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM. David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain
RISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain Potential Conflicts of Interest Financial conflicts of
More informationWhat is New in Acute Pulmonary Embolism? Interventional Treatment. Prof. Nils Kucher University Hospital Bern Switzerland
What is New in Acute Pulmonary Embolism? Interventional Treatment Prof. Nils Kucher University Hospital Bern Switzerland nils.kucher@insel.ch Disclosure of Interest Dr. Kucher received research grants
More informationUltrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism A pulmonary embolism (PE) is
More informationIs Thrombolysis Only for a Crisis?
Is Thrombolysis Only for a Crisis? December 19, 2017 Is Thrombolysis Only for a Crisis? Indications for Thrombolytic Therapy in Patients with Acute Pulmonary Embolism Case Scenario A 28 year old woman
More informationDiagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Summary Number 68 Overview Venous thromboembolism
More informationMassive and Submassive Pulmonary Embolism: 2017 Update and Future Directions
Massive and Submassive Pulmonary Embolism: 2017 Update and Future Directions Kush R Desai, MD Assistant Professor of Radiology Northwestern University Feinberg School of Medicine Chicago, IL Disclosures
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk
More informationPrognostic value of the ECG on admission in patients with acute major pulmonary embolism
Eur Respir J 2005; 25: 843 848 DOI: 10.1183/09031936.05.00119704 CopyrightßERS Journals Ltd 2005 Prognostic value of the ECG on admission in patients with acute major pulmonary embolism A. Geibel*, M.
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21764 holds various files of this Leiden University dissertation. Author: Mos, Inge Christina Maria Title: A more granular view on pulmonary embolism Issue
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationPulmonary hypertension (PH) and right ventricular (RV)
Pulmonary Embolism One-Year Follow-Up With Echocardiography Doppler and Five-Year Survival Analysis Ary Ribeiro, MD; Per Lindmarker, MD; Hans Johnsson, MD, PhD; Anders Juhlin-Dannfelt, MD, PhD; Lennart
More informationSupplementary Online Content
Supplementary Online Content Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a metaanalysis.
More informationAcute pulmonary embolism: risk stratification in the emergency department
Intern Emerg Med (2007) 2:119 129 DOI 10.1007/s11739-007-0033-y 119 REVIEW C. Becattini G. Agnelli Acute pulmonary embolism: risk stratification in the emergency department Received: 16 October 2006 /
More informationCHEST Recent Advances in Chest Medicine
--- --- -- --- CHEST Recent Advances in Chest Medicine J Thrombolytic Therapy for Acute Pulmonary Embolism* A Critical Appraisal ]amie L. Todd, MD; and Vidor F. Tapson, MD Pulmonary embolism (PE) is a
More informationAcute myocardial infarction. Cardiovascular disorders. main/0202_new 02/03/06. Search date August 2004 Nicholas Danchin and Eric Durand
main/0202_new 02/03/06 Acute myocardial infarction Search date August 2004 Nicholas Danchin and Eric Durand QUESTIONS Which treatments improve outcomes in acute myocardial infarction?...4 Which treatments
More informationThe Evidence Base for Treating Acute DVT
The Evidence Base for Treating Acute DVT Mr Chung Sim Lim Consultant Vascular Surgeon and Honorary Lecturer Royal Free London NHS Foundation Trust and University College London NIHR UCLH Biomedical Research
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More informationSingle-Center, Retrospective, Observational Analysis of Patients with Submassive Pulmonary Embolism (PE) Receiving Catheter- Directed Thrombolysis
Single-Center, Retrospective, Observational Analysis of Patients with Submassive Pulmonary Embolism (PE) Receiving Catheter- Directed Thrombolysis John A. Phillips, M.D. OhioHealth Heart and Vascular Physicians
More informationA 50-year-old woman with syncope
Hira Shahzad 1, Ali Bin Sarwar Zubairi 2 1 Medical College, Aga Khan University Hospital, Karachi 2 Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan Ali Bin Sarwar Zubairi Associate
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationUnderstanding haemorrhagic risk following thrombolytic therapy in patients with intermediate-risk and high-risk pulmonary embolism: a hypothesis paper
Open Access To cite: Abraham P, Arroyo DA, Giraud R, et al. Understanding haemorrhagic risk following thrombolytic therapy in patients with intermediate-risk and highrisk pulmonary embolism: a hypothesis
More informationEarly Transoesophageal Echocardiography (TOE) in Cardiac Arrest: A Case Study
Case reports Early Transoesophageal Echocardiography (TOE) in Cardiac Arrest: A Case Study N. SIMPSON, N. ORFORD Intensive Care Unit, The Geelong Hospital, Geelong, VICTORIA ABSTRACT We describe a case
More informationPostoperative Acute Pulmonary Embolism: A Case Report. S Mishra, P Kundra, B Hemavathi, A Badhe, M Ravishankar
ISPUB.COM The Internet Journal of Anesthesiology Volume 13 Number 2 S Mishra, P Kundra, B Hemavathi, A Badhe, M Ravishankar Citation S Mishra, P Kundra, B Hemavathi, A Badhe, M Ravishankar.. The Internet
More informationS (18) doi: /j.ajem Reference: YAJEM 57346
Accepted Manuscript A portrait of patients who die in-hospital from acute pulmonary embolism Hesham R. Omar, Mehdi Mirsaeidi, Bishoy Abraham, Garett Enten, Devanand Mangar, Enrico M. Camporesi PII: S0735-6757(18)30172-4
More informationPE is a difficult diagnosis that may be missed because of non-specific clinical presentation.
Pulmonary embolism (PE) is a relatively common cardiovascular emergency. By occluding the pulmonary arterial bed it may lead to acute life-threatening (3% early mortality rate), but potentially reversible
More informationThe shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolism
Eur Respir J 211; 37: 762 766 DOI: 1.1183/931936.711 CopyrightßERS 211 The shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolism A. Sam*, D. Sánchez*,
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 16 December 1999 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL
More informationAcute and long-term treatment of VTE. Cecilia Becattini University of Perugia
Acute and long-term treatment of VTE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE The goals The acute PE phase After the acute phase Treatment for VTE Goals of acute treatment
More informationEmergency Pulmonary Embolectomy after Failed Thrombolysis in a Community Hospital: A Choice of Institutional Preference?
ISPUB.COM The Internet Journal of Emergency Medicine Volume 5 Number 1 Emergency Pulmonary Embolectomy after Failed Thrombolysis in a Community Hospital: A Choice of F Vandy, G Fromm, P Guentert, W Halloran,
More informationTissue Plasminogen Activator for the Treatment of Deep Venous Thrombosis of the Lower Extremity* Alan Forster, MD; and Philip Wells, MD
review Tissue Plasminogen Activator for the Treatment of Deep Venous Thrombosis of the Lower Extremity* A Systematic Review Alan Forster, MD; and Philip Wells, MD Objective: To assess, by systematic review,
More informationThe principal criterion to characterize acute pulmonary
Vascular Medicine Massive ulmonary Embolism Nils Kucher, MD; Elisa Rossi, BS; Marisa De Rosa, hd; Samuel Z. Goldhaber, MD Background Acute massive pulmonary embolism (E) carries an exceptionally high mortality
More informationAcute Management of Pulmonary Embolism
Acute Management of Pulmonary Embolism Dr Alex West Respiratory Consultant Guy s and St Thomas Hospital London Declarations - none Order of Play Up date in Diagnostic Imaging - CTPA and V:Q SPECT Sub-massive
More informationPulmonary Embolism Newer Concepts and Role of Thrombolysis
CHAPTER 69 Pulmonary Embolism Newer Concepts and Role of Thrombolysis J. P. S. Sawhney, A. Bakhshi, B. Kandpal Introduction Pulmonary embolism (PE) is a common cardiovascular and cardiopulmonary illness
More informationManagement of Pulmonary Embolism. Michael Hooper, M.D., MSc Associate Professor, Pulmonary and Critical Care Medicine Eastern Virginia Medical School
Management of Pulmonary Embolism Michael Hooper, M.D., MSc Associate Professor, Pulmonary and Critical Care Medicine Eastern Virginia Medical School I have no conflicts of interest to report. VTE Overview
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More informationThe Pulmonary Embolism Severity Index in Predicting the Prognosis of Patients With Pulmonary Embolism
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.2.123 The Pulmonary Embolism Severity Index in Predicting the Prognosis of Patients With Pulmonary Embolism Won-Ho Choi 1, Sung Uk Kwon 1,2, Yoon Jung Jwa 1,
More informationManagement of sub-massive and massive pulmonary embolism:
Management of sub-massive and massive pulmonary embolism: Evidence and Controversy Boonsong Patjanasoontorn, MD, FCCP, FCCM Immediate Past President, Thai Society of Critical Care Medicine(TSCCM) Chief,
More informationThe restoration of coronary flow after an
Pharmacological Reperfusion in Acute Myicardial Infarction after ASSENT 3 and GUSTO V [81] DANIEL FERREIRA, MD, FESC Serviço de Cardiologia, Hospital Fernando Fonseca, Amadora, Portugal Rev Port Cardiol
More informationΜακροχρόνια παρακολούθηση ασθενών με πνευμονική εμβολή
Μακροχρόνια παρακολούθηση ασθενών με πνευμονική εμβολή Ευφροσύνη Δ. Μάναλη Λέκτορας Β Πανεπιστημιακή Πνευμονολογική Κλινική ΓΝΑ «Αττικόν» Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών Existing guidelines
More informationTissue Plasminogen Activator in In-Hospital Cardiac Arrest with Pulseless Electrical Activity
Tissue Plasminogen Activator in In-Hospital Cardiac Arrest with Pulseless Electrical Activity Hannah Jordan A. Study Purpose and Rationale Pulseless electrical activity during cardiac arrest carries a
More informationModified Bova score for risk stratification and short-term outcome in acute pulmonary embolism
ORIGINAL ARTICLE Modified Bova score for risk stratification and short-term outcome in acute pulmonary embolism K. Keller 1,2, J. Beule 3, J.O. Balzer 4,5 *, W. Dippold 3 * *Both authors are co-shared
More informationFacilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
More informationThe spectrum of clinical outcome of PE
Practical treatment approach for patients with PE Cecilia Becattini University of Perugia The spectrum of clinical presentation of PE PE-related shock Mild clinical symptoms The spectrum of clinical outcome
More informationCase Report Free Floating Right Heart Thrombus Associated with Acute Pulmonary Embolism: An Unsettled Therapeutic Difficulty
Case Reports in Cardiology Volume 2015, Article ID 364780, 4 pages http://dx.doi.org/10.1155/2015/364780 Case Report Free Floating Right Heart Thrombus Associated with Acute Pulmonary Embolism: An Unsettled
More informationVTE in Children: Practical Issues
VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.
More informationManagement of Intermediate-Risk Pulmonary Embolism
Management of Intermediate-Risk Pulmonary Embolism Stavros V. Konstantinides, MD, PhD, FESC Professor, Clinical Trials in Antithrombotic Therapy Center for Thrombosis und Hemostasis, University of Mainz,
More informationAlveolar-Arterial Oxygen Gradient in the Assessment of Acute Pulmonary Embolism*
Alveolar-Arterial Oxygen Gradient in the Assessment of Acute Pulmonary Embolism* Paul D. Stein, MD, FCCP; Samuel Z. Goldhaber, MD, FCCP; and jerald W. Henry, MS Purpose: The purpose of this investigation
More informationDiagnosis and initial treatment of patients with suspected pulmonary thromboembolism
Diagnosis and initial treatment of patients with suspected pulmonary thromboembolism Pulmonary thromboembolism (PTE) remains a frequently occurring diagnostic problem, with an incidence of approximately
More informationAcute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model
ERJ Express. Published on May 12, 2016 as doi: 10.1183/13993003.00024-2016 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationEpidermiology Early pulmonary embolism
Epidermiology Early pulmonary embolism Sitang Nirattisaikul Faculty of Medicine, Prince of Songkla University 3 rd most common cause of cardiovascular death in the United States, following ischemic heart
More informationThe use of thrombolytic therapy THROMBOLYTIC THERAPY FOR PULMONARY EMBOLISM. Trauma and Critical Care Traumatologie et soins critiques
Trauma and Critical Care Traumatologie et soins critiques Return to December 2000 Table of Contents THROMBOLYTIC THERAPY FOR PULMONARY EMBOLISM Brian M. Katchan, MD Consensus regarding the use of thrombolysis
More informationOpen Access Original Article
Open Access Original Article Prognostic role of simplified Pulmonary Embolism Severity Index and the European Society of Cardiology Prognostic Model in short- and long-term risk stratification in pulmonary
More informationPulmonary embolism: treatment of the acute episode
Pulmonary embolism: treatment of the acute episode Franco Casazza, Loris Roncon*, Francesco Greco** Division of Cardiology, San Carlo Borromeo Hospital, Milan, *Division of Cardiology, S. Maria della Misericordia
More informationSevere pulmonary embolism: Catheter-based thrombolysis and medical treatment
Severe pulmonary embolism: Catheter-based thrombolysis and medical treatment Rolf P. Engelberger, MD Division of Angiology Cantonal Hospital Fribourg & University Hospital Bern, Switzerland Overview Reperfusion
More informationAcute and long-term treatment of PE. Cecilia Becattini University of Perugia
Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One
More informationPulmonary embolectomy for acute massive pulmonary embolism: an analysis of 71 cases
Br Heart J 1988;60:196-200 Pulmonary embolectomy for acute massive pulmonary embolism: an analysis of 71 cases HUON H GRAY, JOHN M MORGAN, MATTHIAS PANETH,* GRAHAM A H MILLER From the Departments of Cardiology
More informationReal life management of CTEPH: patient case
2 nd International Congress on cardiovascular imaging in clinical practice k Real life management of CTEPH: patient case Anastasia Anthi Pulmonary Hypertension Clinic, Attikon University Hospital, Athens
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence Document Final information (version number/stage of process) Addendum to Clinical Guideline 144, Venous thromboembolic diseases in adults: diagnosis, management
More informationVenous Thrombosis. Magnitude of the Problem. DVT 2 Million PE 600,000. Death 60,000. Estimated Cost of VTE Care $1.5 Billion/year.
Venous Thrombosis Magnitude of the Problem DVT 2 Million Postthrombotic Syndrome 800,000 PE 600,000 Death 60,000 Silent PE 1 Million Pulmonary Hypertension 30,000 Estimated Cost of VTE Care $1.5 Billion/year
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence IP1243 Ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism Consultation Comments table IPAC date: Thursday 12 March 2015 1 1 Manufacturer
More informationSachin Kumar Amruthlal Jain, 1 Brijesh Patel, 2 Wadie David, 2 Ayad Jazrawi, 1 and Patrick Alexander Introduction
Hindawi Publishing Corporation Case Reports in Medicine Volume 2014, Article ID 297951, 8 pages http://dx.doi.org/10.1155/2014/297951 Case Report Unloading of Right Ventricle and Clinical Improvement after
More informationOUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION
OUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION FEROZ MEMON*, LIAQUAT CHEEMA**, NAND LAL RATHI***, RAJ KUMAR***, NAZIR AHMED MEMON**** OBJECTIVE: To compare morbidity,
More informationAcoustic Pulse Thrombolysis Treatment
Acoustic Pulse Thrombolysis Treatment BTGVascular.com SETTING THE STANDARD FOR VASCULAR THERAPIES Quickly & safely dissolve thrombus with the EKOS System. The Acoustic Pulse Difference Acoustic Pulse Thrombolysis
More informationMed Sci Monit, 2016; 22: Grade D. Quality Outstanding
Ain and Jaff. Treatment of Submassive Pulmonary Embolism: Knowing When to be Aggressive and When to be Conservative. Curr Treat Options Cardio Med (2015) 17:25. Review Article Akin et al. Catheter-Directed
More information